Holen Sie sich die Stockscreener-App
351.81
0.94%
-3.34
Schlusskurs vom Vortag:
$355.15
Offen:
$352.99
24-Stunden-Volumen:
171.84K
Relative Volume:
0.35
Marktkapitalisierung:
$9.82B
Einnahmen:
$7.46M
Nettoeinkommen (Verlust:
$-326.53M
KGV:
-26.29
EPS:
-13.3803
Netto-Cashflow:
$-282.53M
1W Leistung:
+2.05%
1M Leistung:
+13.46%
6M Leistung:
+8.21%
1J Leistung:
+663.31%
1-Tages-Spanne:
$349.82
$357.50
1-Wochen-Bereich:
$333.46
$365.71
52-Wochen-Spanne:
$37.19
$392.70
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
351.81 | 10.18B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-13 | Eingeleitet | Goldman | Buy |
| 2026-06-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
PRAX Maintains by Goldman Sachs -- Price Target Raised to $575 - GuruFocus
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines Slides as Investors Appear to Lock In Gains After Recent Rally - Quiver Quantitative
Praxis (PRAX) Update: Climbs 1.92% to $376.94 for the Current Session; the Supplied Trading Band Runs From $358.09 to $395.79Percent Below MA - vinanet.vn
Praxis Precision Medicine Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Oppenheimer Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $650 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year HighWhat's Next? - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% HigherStill a Buy? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 388.27 USD - Investing.com Nigeria
Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says - marketscreener.com
Raymond James Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Announces Target Price $945 - Moomoo
Raymond James raises Praxis Precision Medicines price target on pipeline outlook By Investing.com - Investing.com Australia
Raymond James raises Praxis Precision Medicines price target on pipeline outlook - Investing.com Australia
Praxis Precision Medicines (PRAX) Holds Near $366.81 as Consolidation Tightens Between Key LevelsBlock Trade Flow - vinanet.vn
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
Praxis Precision Medicines (PRAX) Edges Higher as Biotech Momentum Holds Above Key SupportQuality Factor - dars.gov.et
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances - simplywall.st
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest? - Yahoo Finance
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800 - Moomoo
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Praxis: Commercial Launch Could Smash Expectations (Video) - Seeking Alpha
RBC Adjusts PT on Praxis Precision Medicines to $462 From $449, Keeps Outperform Speculative Risk Rating - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines PT to $475 From $374, Maintains Buy Rating - marketscreener.com
Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotech Powerhouse with 71.91% Upside Potential - DirectorsTalk Interviews
Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Q2 Earnings Call Highlights - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Estimates By $0.80 EPS - marketbeat.com
PD Small-Cap Value Index Portfolio's Praxis Precision Medicines Inc(PRAX) Holding History - GuruFocus
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Hi - GuruFocus
Wedbush Adjusts PT on Praxis Precision Medicines to $188 From $162, Maintains Underperform Rating - Moomoo
Form 8K Praxis Precision Medicines Inc For: 6 August By Investing.com - Investing.com Nigeria
Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside - TradingView
Praxis Precision Medicines stock hits 52-week high at 366.7 USD - Investing.com Nigeria
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... - Yahoo Finance
Earnings call transcript: Praxis Precision Medicines beats Q2 2026 EPS forecast as shares jump - Investing.com Nigeria
PRAXIS PRECISION MEDICINES, INC. : RBC RAISES TARGET PRICE TO $462 FROM $449 - Bitget
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DeSimone Jill | Director |
Jun 24 '26 |
Sale |
311.32 |
11,600 |
3,611,335 |
2,337 |
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):